[1]. Siegel RL, Miller KD, Jemal A: Cancer statistics, 2019. Ca-Cancer J Clin 2019, 69(1):7-34.
[2]. Froemming A, Potretzke T, Takahashi N, Kim B: Upper tract urothelial cancer. Eur J Radiol 2018, 98:50-60.
[3]. Zini L, Perrotte P, Capitanio U, Jeldres C, Shariat SF, Antebi E, Saad F, Patard JJ, Montorsi F, Karakiewicz PI: Radical versus partial nephrectomy: effect on overall and noncancer mortality. Cancer-Am Cancer Soc 2009, 115(7):1465-1471.
[4]. McKiernan J, Simmons R, Katz J, Russo P: Natural history of chronic renal insufficiency after partial and radical nephrectomy. Urology 2002, 59(6):816-820.
[5]. Gadzinski AJ, Roberts WW, Faerber GJ, Wolf JS, Jr.: Long-term outcomes of nephroureterectomy versus endoscopic management for upper tract urothelial carcinoma. J Urol 2010, 183(6):2148-2153.
[6]. Roupret M, Hupertan V, Traxer O, Loison G, Chartier-Kastler E, Conort P, Bitker MO, Gattegno B, Richard F, Cussenot O: Comparison of open nephroureterectomy and ureteroscopic and percutaneous management of upper urinary tract transitional cell carcinoma. Urology 2006, 67(6):1181-1187.
[7]. Jung H, Giusti G, Fajkovic H, Herrmann T, Jones R, Straub M, Baard J, Osther PJS, Brehmer M: Consultation on UTUC, Stockholm 2018: aspects of treatment. World J Urol 2019, 37(11):2279-2287.
[8]. Smith AK, Stephenson AJ, Lane BR, Larson BT, Thomas AA, Gong MC, Jones JS, Campbell SC, Hansel DE: Inadequacy of biopsy for diagnosis of upper tract urothelial carcinoma: implications for conservative management. Urology 2011, 78(1):82-86.
[9]. Hasan MN, Roupret M, Keeley F, Cracco C, Jones R, Straub M, Traxer O, Osther PJS, Brehmer M: Consultation on UTUC, Stockholm 2018 aspects of risk stratification: long-term results and follow-up. World J Urol 2019, 37(11):2289-2296.
[10]. Margulis V, Shariat SF, Matin SF, Kamat AM, Zigeuner R, Kikuchi E, Lotan Y, Weizer A, Raman JD, Wood CG et al: Outcomes of radical nephroureterectomy: a series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer-Am Cancer Soc 2009, 115(6):1224-1233.
[11]. Fernandez MI, Shariat SF, Margulis V, Bolenz C, Montorsi F, Suardi N, Remzi M, Wood CG, Roscigno M, Kikuchi E et al: Evidence-based sex-related outcomes after radical nephroureterectomy for upper tract urothelial carcinoma: results of large multicenter study. Urology 2009, 73(1):142-146.
[12]. GL C, DH B: Ureteroscopic management of upper tract transitional cell carcinoma in patients with normal contralateral kidneys. The Journal of urology 2000, 164(4):1173-1176.
[13]. Soria F, Shariat SF, Lerner SP, Fritsche HM, Rink M, Kassouf W, Spiess PE, Lotan Y, Ye D, Fernandez MI et al: Epidemiology, diagnosis, preoperative evaluation and prognostic assessment of upper-tract urothelial carcinoma (UTUC). World J Urol 2017, 35(3):379-387.
[14]. Roupret M, Colin P, Yates DR: A new proposal to risk stratify urothelial carcinomas of the upper urinary tract (UTUCs) in a predefinitive treatment setting: low-risk versus high-risk UTUCs. Eur Urol 2014, 66(2):181-183.
[15]. Seisen T, Colin P, Roupret M: Risk-adapted strategy for the kidney-sparing management of upper tract tumours. Nat Rev Urol 2015, 12(3):155-166.
[16]. Simhan J, Smaldone MC, Egleston BL, Canter D, Sterious SN, Corcoran AT, Ginzburg S, Uzzo RG, Kutikov A: Nephron-sparing management vs radical nephroureterectomy for low- or moderate-grade, low-stage upper tract urothelial carcinoma. Bju Int 2014, 114(2):216-220.
[17]. Jeldres C, Lughezzani G, Sun M, Isbarn H, Shariat SF, Budaus L, Lattouf JB, Widmer H, Graefen M, Montorsi F et al: Segmental ureterectomy can safely be performed in patients with transitional cell carcinoma of the ureter. J Urol 2010, 183(4):1324-1329.
[18]. Lughezzani G, Jeldres C, Isbarn H, Sun M, Shariat SF, Widmer H, Arjane P, Graefen M, Perrotte P, Montorsi F et al: Temporal stage and grade migration in surgically treated patients with upper tract urothelial carcinoma. Bju Int 2010, 105(6):799-804.
[19]. KS P, J S: When is partial ureterectomy acceptable for transitional-cell carcinoma of the ureter? J Endourol 2001, 15(4):405-408; discussion 409.
[20]. DS E, JW S, D L, DE P, ML B: Is nephroureterectomy necessary in all cases of upper tract transitional cell carcinoma? Long-term results of conservative endourologic management of upper tract transitional cell carcinoma in individuals with a normal contralateral kidney. Urology 2001, 58(2):174-178.
[21]. MC H, S W, AI S, T C, MD E, CG R: Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology 1998, 52(4):594-601.
[22]. Leow J, Orsola A, Chang S, Bellmunt J: A contemporary review of management and prognostic factors of upper tract urothelial carcinoma. Cancer treatment reviews 2015, 41(4):310-319.
[23]. Li X, Cui M, Gu X, Fang D, Li H, Qin S, Yang K, Zhu T, Li X, Zhou L et al: Pattern and risk factors of local recurrence after nephroureterectomy for upper tract urothelial carcinoma. World J Surg Oncol 2020, 18(1):114.
[24]. Zhai T, Jin L, Feng L, Zhou Z, Liu X, Liu H, Ma W, Lu J, Chen W, Yao X et al: Perioperative Chemotherapy on Survival in Patients With Upper Urinary Tract Urothelial Carcinoma Undergoing Nephroureterectomy: A Population-Based Study. Front Oncol 2020, 10:481.
[25]. Kaag MG, O'Malley RL, O'Malley P, Godoy G, Chen M, Smaldone MC, Hrebinko RL, Raman JD, Bochner B, Dalbagni G et al: Changes in Renal Function Following Nephroureterectomy May Affect the Use of Perioperative Chemotherapy. Eur Urol 2010, 58(4):581-587.
[26]. Lane BR, Smith AK, Larson BT, Gong MC, Campbell SC, Raghavan D, Dreicer R, Hansel DE, Stephenson AJ: Chronic kidney disease after nephroureterectomy for upper tract urothelial carcinoma and implications for the administration of perioperative chemotherapy. Cancer-Am Cancer Soc 2010, 116(12):2967-2973.
[27]. Kang CH, Yu TJ, Hsieh HH, Yang JW, Shu K, Huang CC, Chiang PH, Shiue YL: The development of bladder tumors and contralateral upper urinary tract tumors after primary transitional cell carcinoma of the upper urinary tract. Cancer-Am Cancer Soc 2003, 98(8):1620-1626.